BioSyent Inc.
RX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.94M | 8.87M | 7.36M | 7.65M | 6.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.94M | 8.87M | 7.36M | 7.65M | 6.28M |
| Cost of Revenue | 1.60M | 2.15M | 1.64M | 1.84M | 1.17M |
| Gross Profit | 5.34M | 6.73M | 5.72M | 5.81M | 5.11M |
| SG&A Expenses | 3.75M | 4.24M | 3.88M | 3.73M | 3.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.34M | 6.38M | 5.52M | 5.57M | 4.54M |
| Operating Income | 1.60M | 2.49M | 1.84M | 2.08M | 1.74M |
| Income Before Tax | 1.78M | 2.65M | 1.98M | 2.20M | 1.61M |
| Income Tax Expenses | 349.00K | 702.20K | 525.90K | 582.80K | 455.60K |
| Earnings from Continuing Operations | 1.43M | 1.95M | 1.46M | 1.62M | 1.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.43M | 1.95M | 1.46M | 1.62M | 1.15M |
| EBIT | 1.60M | 2.49M | 1.84M | 2.08M | 1.74M |
| EBITDA | 1.73M | 2.65M | 1.93M | 2.20M | 1.79M |
| EPS Basic | 0.13 | 0.17 | 0.13 | 0.14 | 0.10 |
| Normalized Basic EPS | 0.10 | 0.15 | 0.11 | 0.12 | 0.10 |
| EPS Diluted | 0.12 | 0.17 | 0.13 | 0.14 | 0.10 |
| Normalized Diluted EPS | 0.10 | 0.14 | 0.11 | 0.12 | 0.10 |
| Average Basic Shares Outstanding | 11.26M | 11.26M | 11.25M | 11.27M | 11.50M |
| Average Diluted Shares Outstanding | 11.51M | 11.50M | 11.50M | 11.52M | 11.71M |
| Dividend Per Share | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 |
| Payout Ratio | 28.27% | 20.99% | 27.88% | 24.28% | 31.79% |